RE: Turner Pope18 Aug 2020 16:02
Under the terms of the extended agreement, LG Chem now also has the exclusive
rights to develop and commercialise, on a world-wide basis, Avacta's Affimer PDL1 inhibitor with Affimer XTTM serum half-life extension. That is from the TP analysis but I am not capable of apprreciating why AVCT could not be licencing the PDL1 to Glaxo, Astra, Pfizer, HCM, Teva, Vertex, Oxford Bio etc. etc. themselves. LG Chem are hardly going tro spread the PDL1 around I would have thought.